PLoS ONE (Jan 2010)

Comparable low-level mosaicism in affected and non affected tissue of a complex CDH patient.

  • Danielle Veenma,
  • Niels Beurskens,
  • Hannie Douben,
  • Bert Eussen,
  • Petra Noomen,
  • Lutgarde Govaerts,
  • Els Grijseels,
  • Maarten Lequin,
  • Ronald de Krijger,
  • Dick Tibboel,
  • Annelies de Klein,
  • Dian Van Opstal

DOI
https://doi.org/10.1371/journal.pone.0015348
Journal volume & issue
Vol. 5, no. 12
p. e15348

Abstract

Read online

In this paper we present the detailed clinical and cytogenetic analysis of a prenatally detected complex Congenital Diaphragmatic Hernia (CDH) patient with a mosaic unbalanced translocation (5;12). High-resolution whole genome SNP array confirmed a low-level mosaicism (20%) in uncultured cells, underlining the value of array technology for identification studies. Subsequently, targeted Fluorescence In-Situ Hybridization in postmortem collected tissues demonstrated a similar low-level mosaicism, independently of the affected status of the tissue. Thus, a higher incidence of the genetic aberration in affected organs as lung and diaphragm cannot explain the severe phenotype of this complex CDH patient. Comparison with other described chromosome 5p and 12p anomalies indicated that half of the features presented in our patient (including the diaphragm defect) could be attributed to both chromosomal areas. In contrast, a few features such as the palpebral downslant, the broad nasal bridge, the micrognathia, microcephaly, abnormal dermatoglyphics and IUGR better fitted the 5p associated syndromes only. This study underlines the fact that low-level mosaicism can be associated with severe birth defects including CDH. The contribution of mosaicism to human diseases and specifically to congenital anomalies and spontaneous abortions becomes more and more accepted, although its phenotypic consequences are poorly described phenomena leading to counseling issues. Therefore, thorough follow-up of mosaic aberrations such as presented here is indicated in order to provide genetic counselors a more evidence based prediction of fetal prognosis in the future.